Literature DB >> 20190797

Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer.

Jordan Berlin, Al B Benson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20190797     DOI： 10.1038/nrclinonc.2010.16

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.

Authors:  Josep Tabernero; Teresa Macarulla
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

2.  Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

Authors:  W Scheithauer; B Schüll; H Ulrich-Pur; K Schmid; M Raderer; K Haider; W Kwasny; D Depisch; B Schneeweiss; F Lang; G V Kornek
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

3.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

Review 4.  Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

Authors:  Philip A Philip; Margaret Mooney; Deborah Jaffe; Gail Eckhardt; Malcolm Moore; Neal Meropol; Leisha Emens; Eileen O'Reilly; Murray Korc; Lee Ellis; Jacqueline Benedetti; Mace Rothenberg; Christopher Willett; Margaret Tempero; Andrew Lowy; James Abbruzzese; Diane Simeone; Sunil Hingorani; Jordan Berlin; Joel Tepper
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

5.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

Authors:  David Cunningham; Ian Chau; Deborah D Stocken; Juan W Valle; David Smith; William Steward; Peter G Harper; Janet Dunn; Catrin Tudur-Smith; Julia West; Stephen Falk; Adrian Crellin; Fawzi Adab; Joyce Thompson; Pauline Leonard; Joe Ostrowski; Martin Eatock; Werner Scheithauer; Richard Herrmann; John P Neoptolemos
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

6.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

7.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Authors:  Richard Herrmann; György Bodoky; Thomas Ruhstaller; Bengt Glimelius; Emilio Bajetta; Johannes Schüller; Piercarlo Saletti; Jean Bauer; Arie Figer; Bernhard Pestalozzi; Claus-Henning Köhne; Walter Mingrone; Salomon M Stemmer; Karin Tàmas; Gabriela V Kornek; Dieter Koeberle; Susanne Cina; Jürg Bernhard; Daniel Dietrich; Werner Scheithauer
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544
  7 in total
  20 in total

1.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

2.  Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells.

Authors:  Neha Kabra Woods; Jaya Padmanabhan
Journal:  J Biol Chem       Date:  2013-09-10       Impact factor: 5.157

3.  Effect of arenobufagin on human pancreatic carcinoma cells.

Authors:  Tianjiao Wang; Zhumei Zhuang; Peng Zhang; Yueyue Wang; Lin Mu; Haifeng Jin; Lei Zhou; Xiaochi Ma; Rui Liang; Yuhui Yuan
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

4.  Triptolide and celastrol loaded silk fibroin nanoparticles show synergistic effect against human pancreatic cancer cells.

Authors:  Baoyue Ding; Md Arif Wahid; Zhijun Wang; Chen Xie; Arvind Thakkar; Sunil Prabhu; Jeffrey Wang
Journal:  Nanoscale       Date:  2017-08-17       Impact factor: 7.790

5.  Treatment with near-infrared radiation promotes apoptosis in pancreatic cancer cells.

Authors:  Tomohiko Obayashi; Kohei Funasaka; Eizaburo Ohno; Ryoji Miyahara; Yoshiki Hirooka; Michinari Hamaguchi; Hidemi Goto; Takeshi Senga
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

Review 6.  New developments in pancreatic cancer.

Authors:  Julia B Greer; Randall E Brand
Journal:  Curr Gastroenterol Rep       Date:  2011-04

7.  A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Authors:  N V Rajeshkumar; Zeshaan A Rasheed; Elena García-García; Fernando López-Ríos; Kosaku Fujiwara; William H Matsui; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-07-26       Impact factor: 6.261

8.  Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.

Authors:  Mansi Arora; James M Bogenberger; Amro Abdelrahman; Jennifer L Leiting; Xianfeng Chen; Jan B Egan; Aradhana Kasimsetty; Elzbieta Lenkiewicz; Smriti Malasi; Pedro Luiz Serrano Uson; Bolni Marius Nagalo; Yumei Zhou; Marcela A Salomao; Heidi E Kosiorek; Esteban Braggio; Michael T Barrett; Mark J Truty; Mitesh J Borad
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-21       Impact factor: 3.288

9.  Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells.

Authors:  Haley L Peters; Amit Tuli; Xiaojian Wang; Cuiling Liu; Zenggang Pan; Michel M Ouellette; Michael A Hollingsworth; Richard G Macdonald; Joyce C Solheim
Journal:  Int J Oncol       Date:  2012-07-13       Impact factor: 5.650

10.  Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo.

Authors:  Ji Li; Yang Di; Chen Jin; Deliang Fu; Feng Yang; Yongjian Jiang; Lie Yao; Sijie Hao; Xiaoyi Wang; Sabin Subedi; Quanxing Ni
Journal:  Nanoscale Res Lett       Date:  2013-04-17       Impact factor: 4.703
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.